Apert syndrome

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

5 events
Dec 2025A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1

Kidney Cancer Research Bureau — PHASE1, PHASE2

TrialRECRUITING
Nov 2023Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations

Tyra Biosciences, Inc — PHASE1

TrialRECRUITING
Mar 2023A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer

Janssen Pharmaceutical K.K. — PHASE1

TrialACTIVE NOT RECRUITING
Jun 2021NCCH2006/MK010 Trial (FORTUNE Trial)

National Cancer Center, Japan — PHASE2

TrialRECRUITING
Oct 2020A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer

Eisai Co., Ltd. — PHASE1

TrialACTIVE NOT RECRUITING

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

FINANCIAL LANDSCAPE SUMMARY

0

Total programs

No financial assistance programs currently listed for Apert syndrome.
Check the disease page for updates →

Clinical Trial Landscape

No active clinical trials currently recruiting for Apert syndrome.
Search all trials →
Search clinical trials for Apert syndrome

Recent News & Research

No recent news articles indexed yet for Apert syndrome.
Search PubMed for Apert syndrome

Browse all Apert syndrome news →

Specialist Network

Top 6 by expertise

View all Apert syndrome specialists →

Quick Actions